Alpa Laboratories Peer Comparison

NSE: ALPA | BSE: 532878

₹50.38

₹-2.24 (-4.26%)

As on 30-Oct-2026IST

Market cap

₹105 Cr

Revenue (TTM)

₹111 Cr

P/E Ratio

23.9

P/B Ratio

0.6

Div. Yield

0 %

Edit

	Alpa Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	105	18,671	17,672	16,867	16,088
Revenue (₹ Cr)	111	1,682	2,287	2,570	3,330
Net Profit (₹ Cr)	4.38	273.51	678.07	735.15	720.77
Net Margin (%)	3.64	16.19	28.10	26.88	21.60
RoE (%)	2.37	11.15	19.73	19.16	18.93
Price to Earnings	23.93	62.80	26.56	22.94	22.74
Price-To-Book	0.56	6.95	4.81	3.83	3.88

Income Statement (₹ Cr)

	Alpa Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Operating Revenue	110.63	1,682.47	2,287.33	2,569.77	3,329.63
Total Income	120.21	1,689.83	2,413.29	2,735.39	3,337.47
Total Expenditure	111.72	1,203.91	1,490.75	1,628.14	2,168.88
EBITDA	-1.09	478.55	796.58	941.63	1,160.75
Depreciation	2.26	126.01	78.10	57.58	285.40
EBIT	-3.35	352.55	718.48	884.05	875.35
Interest	0.32	52.11	0.88	7.69	187.51
Other Income	9.58	7.37	125.96	165.62	7.84
Exceptional Items	0.00	12.16	0.00	-49.16	-53.14
Profit before Tax	5.91	319.96	843.56	992.82	642.54
Provision for Tax	1.53	46.45	165.49	257.67	-78.23
Profit after Tax	4.38	273.51	678.07	735.15	720.77

	Alpa Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Shareholder's Funds	186.28	2,591.20	3,586.42	4,202.90	4,144.34
Minority Interest	0.00	0.00	-12.71	0.00	-10.85
Non-Current Liabilities	3.34	266.35	28.74	91.50	758.48
Current Liabilities	52.53	848.06	385.94	627.48	2,681.14
Total Liabilities	242.14	3,705.61	4,037.51	4,921.88	7,246.72

	Alpa Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Non-Current Assets	26.78	2,525.44	1,291.22	770.28	5,578.78
Current Assets	210.90	1,109.77	2,585.66	3,803.22	1,800.86
Total Assets	242.14	3,705.61	4,037.51	4,921.88	7,246.72
Total Debt*	2.51	657.97	0.57	2.50	2,309.68
Net Current Assets	158.37	261.71	2,199.72	3,175.74	-880.28
Contingent Liabilities	13.67	160.01	17.53	370.49	51.57

	Alpa Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Cash From Operating Activities	9.29	342.18	523.24	967.57	537.99
Cash Flow from Investing Activities	-10.88	-325.92	-582.30	-561.67	-369.46
Cash from Financing Activities	2.22	13.62	-46.46	-798.31	-313.53
Net Cash Inflow / Outflow	0.63	29.88	-105.52	-392.41	-145.00

	Alpa Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
ROCE (%)	9.39	11.43	24.97	23.39	14.47
ROE (%)	2.37	11.15	19.73	19.16	18.93
ROA (%)	1.88	7.80	18.69	14.95	9.78
EBIT Margin (%)	-3.03	20.95	31.41	34.40	26.29
Net Margin (%)	3.64	16.19	28.10	26.88	21.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Alpa Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Revenue Growth (%)	0.46	27.91	15.01	10.69	11.06
EBIT Growth (%)	-235.67	58.32	18.45	24.14	13.71
Net Profit Growth (%)	-83.31	149.56	19.61	-9.09	60.98
EPS Growth (%)	-83.31	-3.57	17.73	14.40	80.38
Book Value Growth (%)	8.21	9.67	26.75	-0.34	36.71

	Alpa Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Price / Earnings	23.93	66.62	26.56	21.86	21.06
Price / Book Value	0.56	6.95	4.81	3.83	3.88
Dividend Yield (%)	0.00	0.06	0.34	2.03	0.00
EV/EBITDA	28.01	40.30	20.92	14.61	15.79
Market Cap (₹ Cr)	97.31	6,819.66	11,439.22	21,592.90	17,980.08

	Alpa Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debt to Equity	0.00	0.07	0.00	0.00	0.10
Short term debt to equity ratio	0.01	0.16	0.00	0.00	0.12
Current Ratio	4.01	1.31	6.70	6.06	0.67
Quick Ratio	3.76	0.88	5.59	5.31	0.49
Interest Coverage	19.47	7.14	959.59	130.11	4.43

	Alpa Laboratories	Shilpa Medicare	Caplin Point Lab	Pfizer	Eris Lifesciences
Debtors to sales (%)	36.91	30.84	36.10	7.07	18.98
Asset Turnover	0.48	0.48	0.63	0.52	0.45
Receivable days	151.19	113.81	121.68	26.06	63.88
Inventory Days	53.42	84.76	63.83	65.95	43.27
Payable days	100.34	101.94	108.28	81.01	151.85
Cash Conversion Cycle	104.27	96.62	77.23	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.